Lombard Medical (EVARF) 6-K Lombard Medical Aorfix™ Highlighted at 2014 Society for Vascular Surgery Annual Meeting

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549

Form 6-K

Report of Foreign Private IssuerPursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934June 16, 2014

Lombard Medical, Inc.

(Exact Name of Registrant as Specified in Its Charter)

N/A

(Translation of Registrant’s Name into English)

Cayman Islands	3841	Not applicable
(State or Other Jurisdiction of Incorporation or Organization)	(Primary Standard Industrial Classification Code Number)	(I.R.S. Employer Identification Number)

4 Trident Park
Didcot
Oxfordshire OX11 7HJ
United Kingdom
+44 20 1235 750800

(Address, Including ZIP Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)

Lombard Medical Technologies, Inc.

15420 Laguna Canyon Road

Suite 260

Irvine, CA 92618

(Name, Address, Including Area Code, of Agent for Service)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F X                             Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ⃞

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ⃞

          Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of Lombard Medical Inc. dated June 6, 2014, announcing the highlighting of the company’s Aorfix^TM stent graft at the 2014 Society for Vascular Surgery Annual Meeting.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Lombard Medical, Inc.
		By:	/s/ Ian Ardill
				Ian Ardill
				Chief Financial Officer
Date:	June 16, 2014

Index to Exhibits

Exhibit No.	Description of Exhibit
99.1	Press Release of Lombard Medical Inc. dated June 6, 2014, announcing the highlighting of the company’s AorfixTM stent graft at the 2014 Society for Vascular Surgery Annual Meeting.